Promonitor®-anti-IFX Ref. 507XX30000

  • Email link to this assay page

Quantitative measure of anti-infliximab antibodies.

Promonitor®-anti-IFX is an enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of anti-infliximab antibodies in human serum samples. The amount of anti-infliximab antibodies, when considered in conjunction with the infliximab (IFX, Remicade®) level (Promonitor®-IFX Ref. 5060230000) and clinical findings, like disease activity, contributes valuable information to the physician to assess the efficacy of therapies with IFX, predict infusion-related reactions and loss of clinical response by the patient. Due to its chimeric structure, IFX often raises an unwanted immune response in the treated patient, causing Anti-Drug Antibodies (ADA) to form. All Anti-IFX antibodies are neutralizing anti-idiotypic antibodies which can render the therapy completely useless. It is also known that the presence of high titers of anti-IFX antibodies may be related to severe complications like infusion-related reactions. The correlation between reduced serum IFX concentrations, ADA formation and increased disease activity has been demonstrated in several observational clinical studies in a series of pathologies.

Promonitor®-anti-IFX is a bridging ELISA where microwell strips are provided pre-coated with IFX. The bridging ELISA takes advantage of the two arms of IgG subclasses 1, 2 and 3, to crosslink the IFX coated on the plate. Calibrators, controls and diluted patient samples are added to separate wells, allowing anti-IFX antibodies present to bind to pre-immobilized IFX. Unbound sample is washed away, and HRP-labeled IFX is added to each well. A second incubation allows the HRP-labeled IFX to bind to the antibodies that have become attached to the microwells. After washing away unbound HRP conjugate, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops in a spectrophotometer. The signal obtained is proportional to the amount of anti-IFX binding antibodies in the patient sample.

Optical densities (OD) of the calibrators are plotted to construct the anti-IFX antibodies calibration curve. A four parameter logistic (4PL) model is used to fit the curve. Positive and Negative Controls are used to monitor assay performance. Anti-IFX antibodies titer is calculated by interpolating sample OD in the calibration curve. Interpretation of results in a clinical setting is provided. Warnings for each sample are optionally included; this setting can be configured here.

See also Related assays


Supply your measurement data: Help
Help You can supply your raw data in two ways:
  1. Enter (or Paste) the raw data into the edit box. Use the same format as the example data (i.e. numbers separated by spaces). More...
  2. Select a data file on your computer and press Upload. Most raw data file formats are automatically recognised and processed. Formats not currently supported can be added very quickly. More...
After reviewing other analysis parameters press the Calculate button below to process your results.



Standard Concentrations


Sample IDs


Run Notes

Promonitor® is a trademark of Proteomika, S.L.